コンテンツへスキップ
Merck
すべての画像(1)

資料

B1152050

Bromperidol decanoate

European Pharmacopoeia (EP) Reference Standard

別名:

Decanoic acid 4-(4-bromophenyl)-1-[4-(4-fluorophenyl)-4-oxobutyl]-4-piperidinyl ester

ログイン組織・契約価格を表示する
すべての画像(1)

About This Item

実験式（ヒル表記法）:
C31H41BrFNO3
CAS番号:
75067-66-2
分子量:
574.56
UNSPSCコード:
41116107
NACRES:
NA.24

グレード

pharmaceutical primary standard

APIファミリー

bromperidol

メーカー／製品名

EDQM

アプリケーション

pharmaceutical (small molecule)

フォーマット

neat

保管温度

2-8°C

InChI

1S/C31H41BrFNO3/c1-2-3-4-5-6-7-8-11-30(36)37-31(26-14-16-27(32)17-15-26)20-23-34(24-21-31)22-9-10-29(35)25-12-18-28(33)19-13-25/h12-19H,2-11,20-24H2,1H3

InChI Key

ZINCPWWBSRSXBH-UHFFFAOYSA-N

類似した製品をお探しですか？ 訪問 製品比較ガイド

関連するカテゴリー

詳細

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

アプリケーション

Bromperidol decanoate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

包装

この製品は発行元の薬局方による供給としてお届けします。現在の単位量については、EDQM reference substance catalogueをご覧ください。

その他情報

Sales restrictions may apply.

Choose from one of the most recent versions:

試験成績書（COA）

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact カスタマーサポート

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする

E Smeraldi et al.
Minerva psichiatrica, 37(1), 39-44 (1996-03-01)
We assessed the safety and therapeutic efficacy of bromperidol decanoate in a six-month open trial on 21 patients (13 males and 8 females), mean age 41.3 years, who were no longer in the acute phase and were being treated as
S Quraishi et al.
The Cochrane database of systematic reviews, (2)(2), CD001719-CD001719 (2000-05-05)
Anti-psychotic drugs are the mainstay treatment for schizophrenia. Long-acting depot injections of drugs such as bromperidol decanoate are extensively used as a means of long-term maintenance treatment. To assess the effects of depot bromperidol versus placebo, oral anti-psychotics and other
Marianna Purgato et al.
The Cochrane database of systematic reviews, (9)(9), CD001719-CD001719 (2011-09-09)
Antipsychotic drugs are the mainstay treatment for schizophrenia. Long-acting depot injections of drugs such as bromperidol decanoate are extensively used as a means of long-term maintenance treatment. To assess the effects of depot bromperidol versus placebo, oral antipsychotics and other
A Levi Minzi et al.
Minerva psichiatrica, 33(1), 51-55 (1992-01-01)
An open study in 20 patients (7 M, 13 F, mean age 40 years) has been performed in order to evaluate the effectiveness and the safety of bromperidol decanoate in the long-term treatment of psychotic disorders. Patients were selected according
Marianna Purgato et al.
The Cochrane database of systematic reviews, 11, CD001719-CD001719 (2012-11-16)
Antipsychotic drugs are the mainstay treatment for schizophrenia. Long-acting depot injections of drugs such as bromperidol decanoate are extensively used as a means of long-term maintenance treatment. To assess the effects of depot bromperidol versus placebo, oral antipsychotics and other
関連する文献をすべて表示

ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.

製品に関するお問い合わせはこちら（テクニカルサービス）